Tianjin Finder Chemical: difference between revisions
Diff·revision 20 → 21·01:12, 15 Sep 2025
Difference between revision 20 and revision 21 of Tianjin Finder Chemical. 6 lines changed; the page grew by 1,067 bytes.
| Revision 20 — 06:38, 26 Aug 2025 TallySheetTad (talk) correct the trading name — the short code and the legal name are different things 12,456 bytes +1,700 | Revision 21 — 01:12, 15 Sep 2025 CiteBot (talk) bot: update parent category chain 13,523 bytes +1,067 | ||
|---|---|---|---|
| 85 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | 85 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} |
| 86 | 86 | ||
| + | 87 | PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.{{r|tally}} | |
| + | 88 | ||
| 87 | == Regulatory position and legal status == | 89 | == Regulatory position and legal status == |
| 88 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | 90 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} |
| ⋮ | ⋮ | ||
| 95 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} | 97 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} |
| 96 | 98 | ||
| + | 99 | Two frameworks are named in this article only to say what has ''not'' been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,{{r|gmp}} and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.{{r|iso17025}} Neither assessment is available here for this organisation or for any other covered on this wiki. | |
| + | 100 | ||
| 97 | == References == | 101 | == References == |
| 98 | {{reflist}} | 102 | {{reflist}} |
| ⋮ | ⋮ | ||
| 102 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 106 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 103 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 107 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 108 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 104 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 109 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 110 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | |
| 105 | 111 | ||
| 106 | == Further reading == | 112 | == Further reading == |